One of the cohorts consists of HER2-negative breast cancer patients with somatic mutations in one of the following genes: PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, and ATR. As a result, this trial was reported multiple times by IDICAP, once for each queried gene symbol. This evidence concerns the gene ERBB2 and breast carcinoma.